Matt Kaplan: Okay. That’s great. Thanks, Steve.
Steve Lisi: Thanks, Matt.
Operator: Our next question comes from the line of Yale Jen with Laidlaw & Company. Please proceed with your question.
Yale Jen: Good afternoon, and thanks for taking the questions. For the LungFit PRO, I’m sorry, LungFit PH, you mentioned that you have a number of contracts. So, should we anticipate that you report that as the group later on in the next earning call, or should we anticipate that you will provide some update between this call and the next call in terms of [indiscernible] several contracts being signed?
Steve Lisi: Thanks, Yale. Since the start fiscal year end or at the end of — almost at the end of June and we’re going to report early in August, it’s about six weeks difference between now and then. So I don’t know how much update there will be. You would anticipate that based on the number of contracts we’ve signed, where there’ll probably be a few more by that — we get there August, but it’s not going to be a material difference in six weeks. So but again, we’ll be making progress. I think that there should be a material difference when we report in November for sure. It’s just these are very tight on fiscal year end and fiscal first quarter.
Yale Jen: Understood. That’s helpful. And one other thing in terms of your — you were expecting CE Mark later this year and the question is that, beforehand, there’s a discussion in terms of partnering ex U.S. Any update of that front as of now?
Steve Lisi: Yes, I mean, we’re getting close to CE Mark. So the conversations are certainly progressing with ex U.S. partners now that we kind of see the light with CE Mark. But again, we don’t have it in hand. So I think we will have it in hand in September, maybe October timeframe. So I think that our talks will heat up and we’ll probably see some kind of a partnership in short order after we get the CE Mark in hand. So, we’re pretty comfortable with the profile of the product. I think that our potential partners have seen this profile of the product. They’re pretty happy with it. So things are moving along. I mean, Duncan is with me as well, I don’t know if he has anything else to add, but…
Duncan Fatkin: No, I think that the timing obviously is associated with the CE Mark and there’s really nothing that should slow us down. So from my point of view, there’s no product issue. It’s all about this timing coinciding with CE Mark availability.
Yale Jen: Okay. Maybe just last question here, which is about the UNO in the cancer. I just want to confirm that all the studies — the study so far is in combo, in other words, is the UNO plus the checkpoint inhibitor. Is that correct? Or are there any single agent studies for PK and other aspects?
Steve Lisi: Well, yes, I mean, there’s no PK obviously because it’s not a systemic therapy. But yes, I mean we’ve done multiple studies with monotherapy and even the combination studies that we reported on all had monotherapy arms as well. So, there’s plenty of monotherapy data. And of course, the first in human study is monotherapy. So I mean, you can go to the Beyond Cancer website and see all that data. It’s all there. It’s all out in the open and public. And I encourage you to call the CEO of Beyond Cancer and have a chat with her, and she can walk you through everything. But, yes, there’s a lot of monotherapy data, and it’s obviously very positive.
